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Carboxyl-ester lipase (CEL) is a pancreatic fat-digesting
enzyme associated with human disease. Rare mutations in the
CEL gene cause a syndrome of pancreatic exocrine and endo-
crine dysfunction denoted MODY8, whereas a recombined
CEL allele increases the risk for chronic pancreatitis. More-
over, CEL has been linked to pancreatic ductal adenocarci-
noma (PDAC) through a postulated oncofetal CEL variant
termed feto-acinar pancreatic protein (FAPP). The monoclo-
nal antibody mAb16D10 was previously reported to detect a
glycotope in the highly O-glycosylated, mucin-like C termi-
nus of CEL/FAPP. We here assessed the expression of human
CEL in malignant pancreatic lesions and cell lines. CEL was
not detectably expressed in neoplastic cells, implying that
FAPP is unlikely to be a glycoisoform of CEL in pancreatic
cancer. Testing of the mAb16D10 antibody in glycan microarrays
then demonstrated that it recognized structures containing termi-
nal GalNAc-1,3(Fuc-1,2)Gal (blood group A antigen) and also
repeated protein sequences containing GalNAc residues linked to
Ser/Thr (Tn antigen), findings that were supported by immunos-
tainings of human pancreatic tissue. To examine whether the CEL
glycoprotein might be modified by blood group antigens, we used
high-sensitivity MALDI-TOF MS to characterize the released
O-glycan pool of CEL immunoprecipitated from human pancreatic
juice. We found that the O-glycome of CEL consisted mainly of
core 1/core 2 structures with a composition depending on the sub-
ject’s FUT2 and ABO gene polymorphisms. Thus, among digestive
enzymes secreted by the pancreas, CEL is a glycoprotein with some
unique characteristics, supporting the view that it could serve addi-
tional biological functions to its cholesteryl esterase activity in the
duodenum.
Carboxyl-ester lipase (CEL)3 (EC 3.1.1.13), also designated
bile salt– dependent lipase, is one of four major duodenal
lipases secreted by pancreatic acinar cells (1). In addition, mam-
malian breast glands secrete CEL, alternatively called bile salt–
stimulated lipase, into mother’s milk (2). CEL is involved in the
hydrolysis and absorption of dietary fat, cholesteryl esters, and
fat-soluble vitamins. It constitutes a significant fraction of pan-
creatic juice, around 4% of the total protein content (3).
The 11 exons of the CEL gene code for a short signal peptide
and a globular N-terminal domain of 535 amino acid residues in
which the bile salt– binding site and the catalytic activity of the
enzyme reside (4). The last exon contains a variable number of
tandem repeats (VNTR) that give rise to a flexible C terminus
protruding from the globular core (5). The VNTR encodes
11–amino acid segments that are repeated from 3 to 23 times in
humans (6), with16 repeats being the most common number
(7–9). The variable length of the CEL VNTR makes this gene
and its protein product highly polymorphic in human popula-
tions. In particular, rare mutational events affecting the VNTR
region cause an inherited syndrome of diabetes and pancreatic
exocrine dysfunction (MODY8) (10), most likely because of
protein aggregation and endoplasmic reticulum stress resulting
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from altered repeat sequences (11–13). Moreover, a recom-
bined allele between the VNTR regions of CEL and the neigh-
boring pseudogene CELP is associated with a significantly
increased risk for chronic pancreatitis (14, 15).
The mature form of CEL is heavily glycosylated. Its globular
domain contains a N-linked glycan at the conserved residue
Asn-210 (16 –18), whereas the VNTR domain has a high occu-
pation of O-linked glycans on its threonine, and probably ser-
ine, residues (16, 19), similar to that found in mucinous glyco-
proteins (20). As a consequence of the VNTR length variability
and possible differences in the glycan pool, the molecular mass
of the CEL glycoprotein may span from 60 to 140 kDa (7, 11).
Glycosylation changes are a hallmark of disease, especially
prominent in inflammation and cancer (21). Some studies have
indirectly implicated glycovariants of CEL in malignant disease
by using antisera against embryonic pancreas extracts to search
for acinar cell factors that are absent in the adult pancreas and
re-expressed during oncogenesis (22, 23). Among many anti-
bodies produced against fetal pancreatic tissue, the antibody
mAbJ28 detected a concanavalin A–reactive pancreatic glyco-
protein with estimated molecular mass of 110 kDa (24). This
acinar cell component was given the name feto-acinar pancre-
atic protein (FAPP) (24, 25). FAPP was later reported to have
the same amino acid composition as the N-terminal globular
domain of CEL (26) and postulated to be a CEL variant
expressed in embryogenesis, inflammation, and cancer.
However, whether oncofetal forms of CEL exist has not been
confirmed.
Another antibody that seemingly targets a CEL-related gly-
cotope on FAPP is mAb16D10. This monoclonal antibody was
raised against CEL purified from pancreatic juice of a PDAC
patient (27). In SOJ-6 pancreatic cancer cells, mAb16D10 has
been found to specifically recognize an antigen present on the
plasma membrane (28), to inhibit the growth of tumor xeno-
grafts (28), and to induce cell death by the p53/caspase-depen-
dent apoptotic pathway (27). In human pancreatic tissue sec-
tions, mAb16D10 was reported to discriminate pancreatic
cancer from nonneoplastic tissue and other cancers (29).
We sought to confirm and further characterize the postu-
lated onco-glycoforms of CEL by 1) evaluating human CEL
expression in PDAC surgical specimens, 2) determining the
identity of the 16D10 glycotope by means of glycan arrays, and
3) identifying the O-glycan structures at the CEL mucinous tail
by means of high-sensitivity MALDI-TOF MS. However, we
could not detect CEL expression in neoplastic cells and found
that mAb16D10 did not target an epitope specific for CEL or for
pancreatic cancer tissue. Instead, the antibody showed a high
affinity for blood group A antigens, which led to the finding that
ABO blood group determinants are present on the C terminus
of CEL.
Results
CEL expression in normal pancreas, PDAC, and pancreatic
cancer cell lines
Initially, we performed fluorescent in situ hybridization and
immunohistochemistry for simultaneous detection of CEL
mRNA and protein, respectively, in morphologically normal
Figure 1. CEL expression in the pancreas is restricted to acinar cells. A,
double fluorescent labeling of CEL mRNA (red) and protein (green) in normal
human pancreatic parenchyma. Acinar cells are strongly positive, whereas
ductal cells are negative. The dotted line circumscribes a representative
intralobular duct. White arrowheads indicate the epithelial lining of the duct
lumen. B, a representative islet of Langerhans (circumscribed by dotted line)
devoid of CEL expression. C, high magnification of an acinus with one well-
polarized acinar cell highlighted by the dotted line. Note the basal labeling of
the mRNA and the apical position of the zymogen granules staining positive
for CEL protein. Cell nuclei are stained blue with DAPI. A single z-plane is
shown (0.19 m). Scale bars represent 100 m.
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pancreas (Fig. 1). Our staining method did not detect CEL tran-
scripts or protein in ductal cells or in islets of Langerhans (Fig. 1,
A and B). The acinar cells were strongly positive, as expected,
with CEL transcripts located basally and the protein accumu-
lating apically in the zymogen granules (Fig. 1C). Having estab-
lished the specificity of our method, we evaluated CEL mRNA
and protein expression in adjacent sections from PDAC tumors
by chromogenic staining (Fig. 2). CEL was detectable in pre-
served and atrophic parenchyma (Fig. 2, A, B, E, F). In contrast,
the epithelial lining of acinar-to-ductal metaplasia (ADM), pan-
creatic intraepithelial neoplasia (PanIN), and malignant ducts
were consistently negative (Fig. 2, B–D and F–H).
Next, RT-qPCR was performed on selected areas of un-
stained pancreatic FFPE sections, which were scraped off the
glass slide after comparison with H&E-stained parallel sections.
Neoplastic regions from nine different PDAC patients were
compared with morphologically normal regions from four
patients having nonneoplastic disease. Very low CEL mRNA
levels were detected in the neoplastic areas compared with lev-
els in normal pancreatic parenchyma (Fig. 2I). In addition, the
commonly used pancreatic cancer cell lines BxPC-3, MIA
PaCa-2, and PANC-1 were tested for CEL expression (Fig. 3A).
MIA PaCa-2 and PANC-1 exhibited very low mRNA levels
Figure 2. Pancreatic premalignant and malignant lesions are negative
for CEL expression. A–D, chromogenic in situ labeling of CEL mRNA in sec-
tions from representative pancreatic cancer cases. E–H, chromogenic immu-
nostaining of CEL protein in adjacent sections of A–D. A and E, preserved
pancreatic parenchyma with normal morphology. Acinar cells contain high
levels of CEL mRNA and protein located basally and apically, respectively. B
and F, areas of atrophy with ADM (marked by red asterisks). Both CEL mRNA
and protein cease to be expressed when a lumen is visible. C and G, a PanIN
lesion (circumscribed by dotted line). Insets, magnification of one papillary
protrusion showing negative epithelial cells. The arrow in G indicates
secreted CEL protein present in the duct lumen. D and H, malignant pancre-
atic ducts embedded in desmoplastic stroma. All structures in these areas
were devoid of detectable levels of both CEL mRNA and protein. Scale bars in
A–H represent 100 m. I, RT-qPCR comparing CEL transcript level in PDAC
sections (areas corresponding to D/H; n  9 different patients) with level in
normal pancreatic tissue from patients with nonpancreatic pathologies (n 
4). QARS gene expression was used as normalizing control. Values are
expressed as mean  S.E.
Figure 3. CEL expression is low or absent in pancreatic cancer cell lines. A,
CEL mRNA levels of the pancreatic cancer cell lines BxPC-3, MIA PaCa-2, and
PANC-1 compared with levels in HeLa cells and in stably transfected HEK293
cells (positive control: HEK293_CEL, transfected with a CEL-expressing plas-
mid construct; negative control: HEK293_EV, transfected with empty plasmid
vector). GAPDH gene expression was used as loading control. y-Axis scale is
logarithmic. Error bars represent S.D. from three experimental replicates. B, a
representative Western blot (n  2) of protein lysates from the above cell lines
stained with anti-CEL antibody. GAPDH protein levels in the lower panel was
used as loading control.
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(comparable to the basal levels in HeLa cells). BxPC-3 cells had
a CEL mRNA level comparable with that of native HEK293
cells. Immunoblots stained with an anti-CEL antibody detected
a strong protein band in the control HEK293_CEL line and a
weak band in BxPC-3 cells, but no signal in the other cell lines
(Fig. 3B).
Characterization of the 16D10 glycotope
The mAb16D10 antibody had been produced against puri-
fied CEL (27) and was shown to react well with pancreatic can-
cer tissue sections (29). Because we did not detect CEL mRNA
or protein in neoplastic cells of PDAC tumors, we next sought
an explanation for the reactivity of the mAb16D10 antibody. To
this end, an aliquot of mAb16D10 was analyzed on a glycan
microarray (see “Experimental procedures”). By comparing
bound and unbound structures, we concluded that mAb16D10
had a strong reactivity toward the structural motif GalNAc-
1,3(Fuc-1,2)Gal, which corresponds to the blood group A
antigen (Fig. 4). To verify this result, the antibody was used to
stain normal pancreatic parenchyma from subjects of blood
group A and O. There was strong positivity toward normal
acinar cells from individuals with blood group A, but not in
blood group O pancreatic tissue (Fig. S1, A and C). Similarly,
mAb16D10 specifically stained both erythrocytes and endothe-
lium of blood group A, but not O specimens (Fig. S1, B and D).
We then examined the reactivity of mAb16D10 on pancre-
atic tissue sections from PDAC cases of different ABO pheno-
types. Blood group A cases exhibited a virtually identical stain-
ing pattern when parallel sections were incubated with either
anti-A antibody or mAb16D10 (Fig. 5, A–H). There was strong
reactivity with acinar cells, ducts, blood vessels, and red blood
cells in areas of preserved morphology (Fig. 5, A and E), as well
Figure 5. The mAb16D10 antibody cross-reacts with blood group A anti-
gens in pancreatic cancer tissue. A–H, adjacent tissue sections from a
patient with blood group A immunostained either with mAb16D10 or an
anti-A antibody. I–L, tissue sections from a patient with blood group O immu-
nostained with mAb16D10. A, E, and I, preserved pancreatic parenchyma with
normal morphology. The arrowhead points to pancreatic secretions within a
small duct. B, F, and J, areas of atrophy with acinar-to-ductal metaplasia (ADM,
marked by red asterisks). C, G, and K, PanIN lesions. Inset in K, magnification of
one papillary protrusion. D, H, and L, malignant pancreatic ducts embedded
in desmoplastic stroma. Scale bars represent 100 m.
Figure 4. The mAb16D10 antibody binds strongly to blood group A– containing structures in a glycan array. A, mAb16D10 screened against 609
different glycans on a printed microarray from the Consortium for Functional Glycomics (see “Experimental procedures”). Binding was detected via Alexa Fluor
488 –labeled anti-mouse secondary antibody. B, the 18-glycan structures with the highest affinity shown in decreasing order of binding. Numbers refer to
position in the array in A. C, the structural motif common to all binding structures. This was the terminal glycan having the sequence GalNAc-1,3(Fuc-1,2)Gal-,
which corresponds to the blood group A antigen.
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as with epithelial cells of ADM, PanIN, and malignant ducts
(Fig. 5, B–D and F–H). However, mAb16D10 also stained sec-
tions from PDAC patients with blood group O. Weak positivity,
in a dotlike apical pattern, was observed in normal-looking aci-
nar cells close to the tumor area (Fig. 5I). When ADM was
present nearby, expression of the mAb16D10 glycotope seemed
to increase in the small intralobular ducts connecting the acini
(Fig. 5J). Relatively strong positivity was observed in PanINs
and malignant ducts (Fig. 5, K and L).
Based on the observed staining pattern in blood group O
neoplastic tissue (Fig. 5L), it was clear that mAb16D10 also
recognized some non-A epitope(s). Thus, to further charac-
terize its specificity, mAb16D10 was tested on a second
microarray, consisting of peptides with a varying number of
GalNAc residues conjugated to Ser or Thr residues (Fig. 6).
Among GalNAc-containing peptides, the intensity of the
binding increased as the number of GalNAc--Ser residues
increased, indicating that mAb16D10 bound strongly to
repeating poly-Ser--GalNAc residues (Fig. 6A). Blood
group A antigen bears similarity to the cancer-associated Tn
antigen as they both carry a terminal GalNAc- residue (Fig.
6B). The glycan array experiment was therefore repeated
using an anti-Tn antibody. A certain overlap between the
reactivity of this antibody and that of mAb16D10 was indeed
observed (Fig. 6A). We therefore assumed that mAb16D10
could recognize the Tn antigen in cancerous tissue, and parallel
staining of PDAC sections for these two antigens showed very
similar patterns in blood group O specimens (Fig. 6C). More-
over, we also found that mAb16D10 reacted with gastric and
breast cancer tissue sections from blood group O individuals
(Fig. S2).
mAb16D10 reactivity in pancreatic juice
We were now left with the conundrum that mAb16D10 rec-
ognized the blood group A antigen very well, despite being pro-
duced against purified CEL from pancreatic juice. The most
straightforward explanation would be that CEL, being a heavily
O-glycosylated protein (30), can be decorated with blood group
Figure 6. The mAb16D10 antibody can recognize the cancer-associated Tn antigen. A, comparative binding profile of mAb16D10 (upper part) and an
anti-Tn antibody (lower part) on an array of synthetic Tn glycopeptides from the Consortium for Functional Glycomics (see “Experimental procedures”). The
array consisted of 56 compounds including the blood group A glycan structure (red box). Structures that bound both antibodies are highlighted by yellow
boxes. Only mAb16D10 bound to blood group A antigen structures with high affinity. Note that peptides containing the sequence DVPVEG(Sn)TSTVAPANK
showed increasing binding intensities as the number of GalNAc-conjugated serine residues was increased (array positions 45, 47, 49), whereas the same
peptide sequences devoid of the sugar bound very weakly (positions 46, 48, 50). Compounds on the array and their binding affinities are listed in Table S1. B,
the terminal GalNAc- residue shared by the Tn (GalNAc--Ser/Thr) and blood group A (GalNAc-1,3(Fuc-1,2)Gal) antigens. C, immunostaining with an
anti-Tn antibody or mAb16D10 in adjacent sections of malignant pancreatic ducts embedded in desmoplastic stroma (blood group O individual). Scale bar
represents 100 m.
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A antigens, which then had stimulated mAb16D10 production.
To investigate this hypothesis, we performed immunoprecipi-
tation of CEL directly from pancreatic juice collected from pan-
creatic cancer patients of either blood type A or O. All four
patients had functioning 1,2-fucosyltransferase (as deter-
mined by their FUT2 genotype) and were therefore able to syn-
thesize the H antigen of the ABO blood group system on
secreted glycoproteins. Such subjects are referred to as secre-
tors and compose 80% of the Caucasian population (31, 32).
The immunoprecipitated complexes were subjected to SDS-
PAGE and immunoblotted with anti-CEL, mAb16D10, and
anti-A and anti-Tn antibodies. We performed two experi-
ments, one where the immunoprecipitates were washed with
PBS only (Fig. 7, upper panel) and another where more strin-
gent washings with RIPA buffer were performed, aiming at dis-
sociating possible complexes that CEL might form with other
proteins (Fig. 7, lower panel). The anti-CEL antibody detected
the protein in all samples as a band of around 110 kDa. After
staining with mAb16D10 or anti-A antibody, a band of similar
size was detected in blood group A samples but not in samples
from blood group O individuals (Fig. 7). This observation
strongly supported that CEL could contain terminal blood
group A antigens. Anti-Tn staining was negative with regard to
detecting a band that corresponded to CEL in molecular size. A
high-molecular-mass band at 170 kDa was seen for all anti-
bodies except anti-CEL, but only when mild washing was
applied (Fig. 7, upper panel). This might indicate that a CEL-
binding protein is present in pancreatic juice and that this pro-
tein contains structures with terminal -GalNAc residues rec-
ognizable by all three antibodies.
Characterization of the O-glycome of CEL
Finally, we attempted to detect blood group A epitopes
directly on CEL after immunoprecipitation from pancreatic
juice. The protein band at 110 kDa (Fig. 7) was excised. As
quality control, a small fraction of this band was used for pro-
tein identification by MS after trypsin-cleaved peptides/glyco-
peptides had been extracted. CEL was the major protein species
identified (data not shown). Then, MS profiling of O-glycans in
the excised band was performed using MALDI-TOF-TOF after
-reductive elimination.
The CEL O-glycome was analyzed in three samples (Fig. 8):
two FUT2-positive cases (secretors) of blood group O and A,
respectively, and one FUT2-negative case (nonsecretor) of
blood group O. The latter subject contained a mutation in
the FUT2 gene that leads to a nonfunctional 1,2-fucosyl-
transferase, meaning that there are no H antigens on
secreted glycoproteins to be further converted into A and B
antigens. As described below, the identified O-glycan pool
was in all three cases consistent with ABO and FUT2 geno-
typing of genomic DNA extracted from the patients’ blood
samples (32).
The blood group O/secretor sample (Fig. 8A) was dominated
by the molecular ion m/z 708 which is consistent with a blood
group O antigen (or H antigen) core 1 structure. Core 2 struc-
tures containing the H antigen were also seen with a single (m/z
1158, 1332, and 1519) or two or more LacNAc units (m/z 1607,
1781, 1968, 2056, and 2230) with or without sialic acid (NeuAc)
capping. In the blood group A/secretor sample (Fig. 8B), the
two highest peaks corresponded to the molecular ion at m/z
953, which is consistent with a core 1 blood group A structure,
and its precursor at m/z 708 (H antigen). A higher molecular
mass structure containing one blood group A antigen on each
antenna was detected at m/z 1822. LacNAc extensions of two
units or more were not seen in this sample.
When CEL was isolated from the pancreatic juice of a non-
secretor patient (Fig. 8C), the glycan pool lacked the molecular
ion m/z 708. As a consequence, the Gal residue of the precursor
Gal-1,3-GalNAc (m/z 534, not detected) could only undergo
sialylation and therefore m/z 895 (monosialylated) and 1257
(disialylated) were the two most abundant structures. Core 2
structures were also seen at m/z 983, 1344, 1433, 1519, 1607,
1794, 1882, and 1968. Fucoses were only part of core 2 struc-
tures (m/z 1519, 1607, and 1968) attached most likely to a
GlcNAc residue.
Figure 7. Immunoprecipitated CEL protein from pancreatic juice reacts with mAb16D10 and an anti-A antibody but not with anti-Tn. Co-immunopre-
cipitation (upper panel) and immunoprecipitation (lower panel) of CEL were performed on four juice samples, followed by parallel immunoblotting with
anti-CEL, mAb16D10, anti-A, or anti-Tn antibodies. CEL was detected at around 110 kDa in all samples. The mAb16D10 and anti-A antibodies gave the same
staining pattern in samples from blood group A cases (juices 3 and 4). Tn did not react with CEL but showed reactivity toward a protein of higher molecular mass
regardless of blood group (upper panel). Two different anti-CEL antibodies were used: the mouse mAb As20.1 for immunoprecipitation and a rabbit polyclonal
antibody (13) for immunoblotting. The dashed line indicates that the membrane part to the left was cut and exposed for a longer time to achieve better signals.
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Structural assignment was facilitated by all molecular ions
from the MS spectra being examined by MS/MS analysis. In Fig.
9, fragmentation patterns of the selected ions m/z 1781, 1822,
and 1794 (from spectra in Fig. 8, A–C, respectively) are shown.
Moreover, three peaks observed in the blood group O secretor
and nonsecretor samples had identical m/z values (1519, 1607,
and 1968; Fig. 8, A and C). The fragmentation pattern showed
that they corresponded to glycans of the same composition but
Figure 8. The mucinous domain of CEL contains glycans reflecting the patients’ ABO and FUT2 status. The O-glycan pool from the pancreatic juice of
three PDAC cases was investigated by MALDI-TOF MS after alkaline -elimination and permethylation. The O-glycan population was composed of core 1 and
core 2 structures. A, spectrum showing O-linked glycans from a blood group O FUT2-positive (secretor) case. Inset, 34 magnification in the m/z range
1500 –2400 showing core 2 extended structures of less abundance. B, corresponding spectrum from a blood group A FUT2-positive (secretor) case, with 15
magnification in the m/z range 1190 –2400. C, corresponding spectrum from a blood group O FUT2-negative (nonsecretor) case, with a 52 magnification in
the m/z range 1500 –2400. All molecular ions are present in singly charged sodiated form ([MNa]). Major peaks are annotated with their proposed
carbohydrate structure, according to the symbolic nomenclature adopted by the CFG (66). Putative structures are based on monosaccharide composition, data
from the MS/MS analysis of all molecular ions and knowledge of the biosynthetic pathways for O-linked glycans. MS and MS/MS spectra were annotated
manually with the aid of the semi-automated tool GlycoWorkbench (65). When structures have not been unequivocally defined from MS/MS information, the
monosaccharide is shown after a bracket.
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with different architecture because of the position of the fucose
residue. Such differences are exemplified in Fig. S3 where two
diverging fragmentation patterns of m/z 1519 are shown.
Characterization of the O-glycome of recombinant CEL
After studying native CEL isolated from pancreatic juice, we
asked whether O-glycosylation of the recombinant protein
expressed in human cell lines would reflect ABO/FUT2 status
of the host cells. We started by analyzing HEK293 cells stably
transfected with a CEL construct containing 16 VNTR repeats
(11, 12) as this line is a commonly used system for expressing
mammalian glycoproteins. Genotyping of the cells, performed
as described previously (32), predicted they derived from a
blood group O and FUT2-positive individual. Secreted CEL
protein was purified and analyzed for O-glycans in the same
way as for pancreatic juice. A relatively diverse pool of O-gly-
cans was detected (Fig 10A) with around half of the signal inten-
sity corresponding to core 2– based structures. No ABO blood
group antigens were detected on the secreted CEL protein
even though the cells were FUT2-positive. To verify that the
detected O-glycans originated solely from the mucinous domain
of CEL, we analyzed HEK293 cells expressing CEL-TRUNC, a
construct in which a stop codon had been introduced immedi-
ately before the VNTR region (11, 12). Only two glycan peaks
were detected (Fig. S4A). They had similar molecular mass and
relative abundance as the two glycans detected in a DMEM
Figure 9. MALDI-TOF/TOF-MS/MS fragmentation spectra confirm the annotation of selected precursor ions from the CEL O-glycome. Molecular ions
m/z 1781, 1822, and 1794 from Fig. 8, A–C, respectively, underwent collision-induced dissociation and the resulting fragmentation spectra are shown. Arrows
pointing from the dashed line indicate the loss of a specific fragment from the precursor ion. All fragment ions are [MNa]. When structures have not been
unequivocally defined from MS/MS information, the monosaccharide is shown after a bracket.
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containing 10% FBS sample (Fig. S4B). This confirmed that only
the mucinous domain of recombinant CEL underwent O-gly-
cosylation in our model system.
Finally, we analyzed the CEL O-glycome after the construct
had been transfected into cancer cell lines from the two major
tissues of CEL expression (pancreas: MIA PaCa-2 and PANC-1
cells; breast: SK-BR-3 cells). Genotyping predicted that both
pancreatic cell lines were of blood group O, with PANC-1 stem-
ming from a FUT2-positive and MIA PaCa-1 from a FUT2-
negative individual. In both lines and regardless of secretor sta-
tus, only one major glycan peak corresponding to a disialylated
core 2 structure (m/z 1257) was found (Fig. 10, B and C). The
SK-BR-3 cell line had an A1O genotype (  blood group A) and
was FUT2-positive. Some core 2 structures were detected (m/z
1344, 1706, 1794, and 2156), but no H or A antigens could be
seen (Fig. 10D). Thus, similar to the pancreatic cell lines, SK-
BR-3 cells were unable to glycosylate CEL in the same selective
way as seen in pancreatic juice samples.
Discussion
CEL has been linked to the autosomal dominantly inherited
pancreatic syndrome MODY8 (10) and to idiopathic chronic
pancreatitis (14). However, whether CEL has a role in pancre-
atic malignancies is still an open question. No genome-wide
association studies of pancreatic cancer have so far identified
any risk SNPs within or close to the CEL gene (33, 34). Neither
the CEL-HYB variant (the allele predisposing for chronic pan-
creatitis) nor specific CEL VNTR lengths were enriched among
pancreatic cancer cases compared with controls (8, 35). Never-
theless, the identification and characterization of FAPP, a pos-
tulated oncofetal variant of CEL with six VNTR repeats, has
raised the possibility that glycoisoforms of CEL could serve as
diagnostic markers or even targets for treatment in pancreatic
cancer (27–29, 36).
In the current study, by using complementary techniques, we
found that CEL was not detectably expressed in either neoplas-
tic cells of PDAC tissue sections or in the pancreatic cancer cell
lines examined. The only exception was BxPC-3 cells, where a
weak protein band that might correspond to CEL was detected,
despite the mRNA level being as low as in native HEK293 cells.
Notably, BxPC-3 is a cell line derived from a moderately well-
differentiated adenocarcinoma with WT KRAS gene (37, 38),
and therefore not fully representative for PDAC tumor cells.
We observed that CEL expression disappeared when acinar-to-
ductal metaplasia was present, confirming that the protein is a
marker of pancreatic acinar cells only when these remain polar-
ized and in acini-like arrangement. Our results are consistent
with those of Reuss and coworkers (39). When they examined
25 ductal or mucinous adenocarcinomas from the pancreas, all
cases were negative for CEL mRNA by in situ hybridization.
Notably, a single case of pancreatic acinar cell carcinoma
showed slightly positive expression (39).
Our results therefore support the conclusion that CEL is
unlikely to correspond to the oncofetal marker FAPP. More-
over, we find it unlikely that there is a cancer-specific num-
ber of VNTR repeats in CEL. Rather, we suggest that the
SOJ-6 cell line used in previous studies either was derived
from a subject with only six VNTR repeats or mutated to this
repeat number because of the inherent genetic instability of
cancer cells.
Because acinar pancreatic markers expressed only during
embryogenesis and oncogenesis have been identified and we
could not detect CEL in neoplastic tissue or cells, we won-
dered which antigen the anti-CEL antibody mAb16D10 did
detect in pancreatic neoplastic cells (22, 23). Knowing that
mAb16D10 reacts with the highly O-glycosylated C-terminal
of CEL (28), we tested the antibody against an array of more
than 600 different mammalian glycan structures. Glycans
containing the blood group A antigen consistently showed
the highest binding (Fig. 4). The presence of blood group
antigens in the O-glycome of CEL was then verified directly
on CEL protein isolated from pancreatic juice (Figs. 7 and 8).
Based on the finding of H and A antigens attached to CEL, we
assume that the protein, when isolated from blood group B
individuals, will be modified by blood group B antigens, but
this remains to be shown.
The samples investigated, as well as the juice sample used for
mAb16D10 production, all stemmed from patients operated
for pancreatic cancer. It will therefore be necessary to analyze
pancreatic juice from healthy subjects to determine whether
the same glycan structures are present as in our PDAC patients.
Notably, aberrant glycosylation is a common characteristic for
malignant transformation (40). This is in line with our observa-
tion that the examined cell lines (Fig. 10) had a generally limited
capacity to O-glycosylate CEL and did not attach blood group
antigens to the protein.
It is perhaps not surprising that CEL’s mucin-like C-terminal
domain contains blood group antigens. Mucinous O-glycans
consist mostly of core 1– 4 structures further elongated with
lactosamine chains and terminated by fucose and sialic acid
(41). Therefore, the presence of ABH or Lewis-type blood
group antigens are not unusual on such proteins (42). In studies
of bile salt–stimulated lipase, the milk counterpart of CEL, the
threonine residues flanking the consensus sequence PVPP of
the mucinous domain were proposed to carry O-glycans (19),
and terminal Lewis antigens Lea, Leb, and Lex were suggested to
be present on this protein region (19, 43). Nevertheless, as far as
we know, no previous study has detected blood group antigens
directly on pancreatic CEL using high-sensitivity MS.
The antibody mAb16D10 also showed reactivity against Tn
motifs. Truncation of the O-glycans in CEL and exposure of
the first GalNAc residue (GalNAc1-O-Ser/Thr) might have
explained the reactivity of mAb16D10 toward both A and Tn
antigens. However, in the MS analysis of purified CEL protein
we did not detect any peak at m/z 330 corresponding to Tn. A
peak at m/z 691 initially suggested a sialylated Tn structure
( STn antigen), but this was not consistent with the predicted
glycan fragmentation pattern obtained when MS/MS was per-
formed. Moreover, in blots of immunoprecipitates, no band
matching CEL in size was seen with the anti-Tn antibody,
although this antigen might be present in a higher-molecular-
mass protein of 170 kDa protein that co-precipitated with
CEL (Fig. 7, upper panel). Taken together, we find that
mAb16D10 has reactivity toward Tn, but that CEL purified
Carboxyl-ester lipase contains ABO blood group determinants




























Figure 10. The O-glycome of recombinant CEL is dramatically altered in cancer cell lines. A–D, the O-glycan pool of recombinant CEL expressed in HEK293
(A), pancreatic cancer (B, PANC-1; C, MIA PaCa-2), and breast cancer (D, SK-BR-3) cell lines were investigated by MALDI-TOF MS after alkaline -elimination and
permethylation. The O-glycan population varied with the cellular expression system employed. No ABO blood group antigens were detected in any cell line.
See Fig. 8 legend for further information about the spectra.
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from pancreatic juice of PDAC patients does not seem to carry
this antigen in detectable amounts. We speculate that the stain-
ing of mAb16D10 observed in gastric and breast cancer (Fig. S2)
could be because of Tn positivity and therefore consistent with
the pancarcinoma nature of this antigen (44, 45).
CEL is, in some respects, unique among digestive enzymes of
the pancreas. The protein is expressed in several nonacinar cell
types and has been linked to nonpancreatic pathogenic processes
(e.g. Ref. 46). Our finding that the C-terminal mucin-like domain
of CEL can be modified by blood group antigens should therefore
stimulate discussions about this heavily glycosylated region and its
significance for CEL function. Neither chicken nor fish CEL con-
tain the VNTR region (47), and truncated human CEL variants
(devoid of the VNTR) are enzymatically active (14, 48, 49). Thus,
the C-terminal domain is clearly dispensable for the catalytic activ-
ity of the protein although a role in substrate specificity cannot be
ruled out. It is conceivable that O-glycosylation serves to increase
the stability of CEL as the C-terminal region bears amino acid
similarity to protein sequences that can be a signal for proteo-
lytic degradation
(50, 51).
Another possibility is that CEL, through its C-terminal
region, contributes to the mucosal barrier in the gastrointesti-
nal tract. A main role of intestinal mucins is to provide lubrica-
tion and create a barrier that will prevent infection by the large
number of microorganisms that populate the gut (52). This
function is exerted through the ability of O-glycans to retain
water and form mucus gels (53). Bearing in mind that CEL
composes up to 4% of the pancreatic acinar proteins (3), the
molecule could to some extent add to the gastrointestinal
mucosal barrier, with the potential of interacting with intestinal
microorganisms (54 –56). Even the presence of blood group
antigens on CEL might be understood in this perspective. In the
analyzed juice samples, the identified glycan pools of CEL were
fully consistent with the patients’ ABO and FUT2 genotypes,
with the H antigen core 1 structure being one of the most abun-
dant motifs detected in the secretor samples. ABO blood
groups are genetically determined factors that modulate the
interaction between host and intestinal microbiota as well as
the flora composition itself, by providing carbohydrate antigens
that act as anchoring sites for commensal bacteria (54, 57).
ABO blood group status convincingly associates with risk for
developing pancreatic cancer (31–33, 58). The mechanistic
basis for this association remains to be explained although
cross-reactivity between blood group IgM isoagglutinins with
blood group–like tumor-associated carbohydrate antigens has
been suggested as an explanation (59). Also for chronic pancre-
atitis, a study has reported that ABO blood group status, in
particular the B phenotype, is a risk factor for this inflammatory
condition (60, 61). However, others have found no association
between ABO blood groups and chronic pancreatitis (62, 63).
Moreover, FUT2-negative status has been linked to chronic
pancreatitis (60, 61) but not to pancreatic cancer (31, 32), and it
is an open question whether the inactivation of the FUT2
gene product represents a detrimental or beneficial effect with
regard to human health. In conclusion, the variability in the
overall glycosylation patterns of secreted gastrointestinal pro-
teins, including CEL, could play a role in the susceptibility to
pancreatic diseases. We foresee that this will constitute an
interesting topic for studies in the years to come.
Experimental procedures
Antibodies
Three different anti-CEL antibodies were used: a polyclonal
rabbit antiserum (against peptide sequence 299 – 427 of the
CEL globular domain) for immunostainings (Sigma-Aldrich,
cat. HPA052701), a polyclonal rabbit antiserum for immuno-
blotting (generated against the truncated CEL form pV562X,
recently published in Ref. 13), and the mouse mAb As20.1 for
immunoprecipitation (raised against the CEL globular domain,
a generous gift from Prof. Olle Hernell, Umeå University, Swe-
den). The antibody mAb16D10 has been described previously
(27–29). Anti-Tn antibody was a generous gift from Prof. Ulla
Mandel (Copenhagen University, Denmark). Mouse monoclo-
nal anti-A (sc-69951) and goat polyclonal anti-GAPDH anti-
bodies (sc-20357) were from Santa Cruz Biotechnology. Sec-
ondary antibodies were HRP-donkey anti-mouse (Invitrogen,
cat. 626520), HRP-donkey anti-goat (Novus Biologicals, cat.
NB7379), FITC-donkey anti-rabbit (Jackson ImmunoResearch
Laboratories, cat. 711-095-152), and HRP-goat anti-rabbit (Invit-
rogen, cat. 656120) and Alexa Fluor 488 anti-mouse (Invitrogen,
cat. A-10680). MACH3 anti-mouse (cat. M3M530H) or anti-rab-
bit HRP-conjugated polymer (cat. M3R531H) were from Biocare
Medical.
Human pancreatic cancer samples
FFPE pancreatic tissue blocks from either blood group A or
blood group O subjects were selected from a cohort of quality-
controlled PDAC cases that had been genotyped to determine
ABO and FUT2 status, as described earlier (32). Pancreatic juice
was obtained from patients undergoing the Whipple procedure
for resection of pancreatic head tumors. After transection of
the pancreas, the distal, dilated pancreatic duct was cannulated,
and a sample of juice was suctioned out and stored at 80 °C
immediately. cOmplete Protease Inhibitor mixture (Roche, cat.
11697498001) was added when samples were thawed for anal-
ysis. Juice samples for the study were selected based on the
patients’ ABO and secretor phenotype. The patients had con-
sented to the study, which was approved by the Regional Ethical
Committee of Western Norway and performed according to
the Helsinki Declaration.
Cell cultures
Human pancreatic cancer cell lines (BxPC-3, MIA PaCa-2,
PANC-1) and HeLa cells (CCL-2) were obtained from Ameri-
can Type Culture Collection (ATCC). HEK293 cells (Clontech)
stably transfected with pcDNA3.1/V5-His plasmids containing
either WT CEL, CEL-TRUNC, or no insert were the same as
described previously (11, 12). PANC-1, HeLa, and HEK293 cells
were cultured in DMEM (Sigma-Aldrich) with 500 g Geneti-
cin (G-418; Invitrogen), 10% FBS (Invitrogen), and 100 units/ml
penicillin/streptomycin. BxPC-3 were maintained in RPMI
1640 medium (Sigma-Aldrich) supplemented with 10% FBS
and 100 units/ml penicillin/streptomycin. MIA PaCa-2 cells
were cultured in DMEM supplemented with 10% FBS, 2.5%
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horse serum (ATCC, cat. 30-2040), and 100 units/ml penicillin/
streptomycin. Human breast cancer cell line SK-BR-3 (ATCC)
was grown and maintained in McCoy’s 5A medium with 10%
FBS and 100 units/ml penicillin/streptomycin. All cells were
cultured in a standard humidified incubator at 37 °C in a 5%
CO2 atmosphere.
Electroporation of cancer cell lines
The 4D-Nucleofector instrument (Lonza) was used. One
million MIA PaCa-2, PANC-1, or SK-BR-3 cells were electro-
porated (DN-100 or EO-137 programs) in presence of 2 g of
the CEL construct in 100 l of SF or SE buffers (Lonza cat.
V4XC-2012 and V4XC-1012). After the pulse application, the
cells were incubated for 10 min in serum-free RPMI medium at
37 °C in 5% CO2 before they were transferred to 60 mm dishes
with standard growth medium. G418 was added 48 h post
transfection at a concentration of 1 mg/ml. After 2–3 weeks of
G418 selection, antibiotic-resistant cells were transferred to
T75 flasks and maintained in 500 g/ml G418. When cells
reached 90% confluency, the growth medium containing
secreted proteins was collected, filtered through 0.22-m
syringe filters, and concentrated 10 times in a vacuum concen-
trator. CEL was immunoprecipitated from the concentrated
sample by employing the anti-CEL As20 antibody.
Immunohistochemistry
FFPE pancreatic tissue sections (3–5 m) were placed onto
SuperFrost Plus Adhesion slides (Menzel-Gläser Laboratories),
dried overnight at 56 °C, deparaffinized in xylene, gradually
rehydrated with decreasing concentrations of ethanol, and
washed with distilled water and PBS containing Tween 0.05%
(v/v). The slides were then incubated in Tris-EDTA buffer (pH
9) in a pressurized heating chamber at 120 °C for 1 min. Next,
the slides were cooled down under running tap water and incu-
bated at 4 °C overnight with the antibodies mAb16D10 (1:100
dilution), anti-A (1:2000), or anti-CEL (1:100) (Sigma-Aldrich),
or for 1 h at room temperature with anti-Tn (undiluted super-
natant). Blocking of endogenous peroxidase activity was done
by incubating the sections in an aqueous solution of 3% hydro-
gen peroxide (v/v) for 5 min at room temperature. Primary
antibody detection was performed with MACH3 anti-mouse or
anti-rabbit HRP-conjugated polymers (Biocare Medical) using
two incubations of 20 min with vigorous washing after each
step on a rocking platform. Staining was visualized by develop-
ing with 3,3-diaminobenzidine as substrate. The sections were
counterstained with Mayer’s hematoxylin (Dako) for 1 min and
then dehydrated in alcohol, cleared in xylene, and eventually
mounted with permanent mounting media.
In situ hybridization
Using a custom-made CEL-specific probe covering exons
2–7, the RNAscope 2.0 HD assay was employed according to
the supplier’s instructions (Advanced Cell Diagnostics). Briefly,
after deparaffinization and rehydration, tissue sections were
sequentially treated with endogenous hydrogen peroxidase
block solution for 10 min at room temperature followed by an
immersion in a 100 °C preheated retrieval solution for 15 min
and subjected to protease digestion at 40 °C for 30 min, rins-
ing with distilled water after each step. The sections were
then hybridized with the CEL probe at 40 °C for 2 h in a
HybEZ oven (Advanced Cell Diagnostics). After wash buffer
steps, signal detection and amplification were performed
using the RNAscope 2.0 HD detection reagents (Advanced
Cell Diagnostics, cat. 322310), starting with the application
of the signal enhancer solutions, then washing vigorously
between each step and eventually adding 3,3-diaminobenzi-
dine as substrate for HRP. The sections were counterstained
with Mayer’s hematoxylin for 1 min and then dehydrated in
alcohol, cleared in xylene, and eventually mounted with perma-
nent mounting media. Images were acquired at various mag-
nifications using a MC170HD camera attached to a DM2000
LED microscope (Leica) and processed using Leica Applica-
tion Suite V4.8 software.
When in situ hybridization was combined with immunofluo-
rescence, the RNAscope 2.0 HD detection system with alkaline
phosphatase (Advanced Cell Diagnostics, cat. 310036) was first
used in conjugation with the VECTOR Red fluorescent sub-
strate (Vector Laboratories, cat. SK-5100). The sections were
then incubated with anti-CEL antibody (1:100) (Sigma-Al-
drich) overnight, and thereafter with secondary antibody (don-
key anti-rabbit IgG-FITC; 1:50) for 1 h. All washing steps were
performed using TBS containing Tween 0.05% (w/v) when
alkaline phosphatase was used instead of HRP. For mounting,
Gold Antifade Solution with DAPI (Invitrogen) was used.
Images were collected using a SP5 AOBS confocal microscope
(Leica Microsystems) with 40/1.4 NA and 63/1.4 NA HCX
Plan-Apochromat oil immersion objectives, 1.2 airy unit
pinhole aperture, and appropriate filter combinations.
Images were acquired with 405 Diode and Argon ion/Argon
Krypton lasers (Leica). The obtained images were merged
and processed using Photoshop CC and Adobe illustrator
CC (Adobe Systems).
RNA isolation and real-time quantitative PCR (RT-qPCR)
FFPE tissue sections (3–5 sections, 10 m each) from the
tumor, corresponding to either neoplastic areas or morpholog-
ically preserved pancreatic parenchyma, were scraped off from
the glasses after comparison with parallel sections stained with
H&E. After deparaffinization, RNA was isolated using the
RNeasy FFPE Kit (Qiagen, cat. 73504) or the RNeasy Micro Kit
(Qiagen, cat. 74004), according to the manufacturer’s instruc-
tions. For cDNA synthesis, reverse transcription was per-
formed on 100 ng RNA utilizing the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems/Thermo Fisher
Scientific). Specific predesigned PCR primers/probe sets were
purchased from Applied Biosystems (CEL: Hs 01068709_m1;
QARS: Hs00192530_m1, and GAPDH: Hs02758991_g1 as nor-
malizing control). RT-qPCR was performed using TaqMan
Universal PCR Master Mix (Applied Biosystems, cat. 4440040)
following the manufacturer´s instructions. The PCR conditions
were 40 cycles of denaturation at 95 °C for 15 s followed by
combined annealing/extension at 60 °C for 1 min. Fluorescent
intensity was measured, and results were processed with SDS
software, version 2.2 (Applied Biosystems).
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Cell lysis and Western blot analyses
Pellets from cultured cells were washed with ice-cold PBS,
treated with ice-cold RIPA lysis buffer (Thermo Fisher Scien-
tific, cat. 89900) and centrifuged for 30 min at maximum speed
at 4 °C. Fifteen g of total protein was mixed with sample buffer
(Life Technologies, cat. NP0007) and reducing agent (Invitro-
gen, cat. NP009), boiled at 90 °C for 5 min and resolved in
NuPAGE Novex 7% Tris acetate gels. Separated proteins were
transferred to PVDF membrane following standard protocols,
then immunoblotted with polyclonal rabbit anti-CEL antibody
(1:10000) (13). Staining with anti-GAPDH antibody (1:500) was
used as loading control. Blots were developed using Amersham
ECL Prime Western Blotting Detection Reagent (GE Health-
care Life Sciences, cat. RPN2232) and images were detected on
the Syngene G:Box XR5 chemiluminescent imaging system
(ISS).
Glycan arrays
An aliquot of mAb16D10 was analyzed by glycan microarray
technology at the Consortium for Functional Glycomics at
Emory University, Atlanta, GA. The antibody was incubated at
a concentration of 50 g/ml on a Mammalian Printed
Glycan Array Version 5.2 (609 structures, available on www.
functionalglycomics.org/glycomics/publicdata/primaryscreen.
jsp)4 or on a glycopeptide array (56 compounds, Table S1), and
probed for binding using fluorescent Alexa Fluor 488 anti-
mouse antibody (Invitrogen, cat. A-10680). On the latter array,
also an anti-Tn antibody was probed. The arrays were pro-
cessed using published methods (64). Binding experiments
were done in replicates of six, removing the highest and lowest
values from each replicate set and calculating the mean binding
efficiency from the remaining four values.
Immunoprecipitation
CEL glycoprotein was purified from pancreatic juice or con-
centrated conditioned growth medium with the Pierce Co-Im-
munoprecipitation Kit (Thermo Fisher Scientific, cat. 26149) as
follows: 50 – 400 l pancreatic juice (protein concentration
between 0.8 and 5.4 g per l) or 1– 4 ml of medium was incu-
bated in a spin-column containing immobilized antibody to the
Agarose resin (As20.1 antibody for CEL or unspecific mouse
immunoglobulin for negative control). The sealed columns
were incubated overnight at 4 °C on a rotating wheel. Washing
steps were performed using either PBS or RIPA buffer for
immunoprecipitation (Merck Millipore, cat. 20-188), and elu-
tion was achieved using 50 mM Tris-HCl, pH 8, with 2.5% w/v
SDS. Five l eluate was separated by standard SDS-PAGE
(SDS-PAGE) and immunoblotted with polyclonal rabbit anti-
CEL antibody (1:10000) (13), mAb16D10 (1:100), anti-A
(1:500), or anti-Tn (1:5) antibody. All incubations were done
overnight at 4 °C on a rocking platform. For MS analysis, the
rest of the eluted protein was subjected to SDS-PAGE electro-
phoresis and the resulting gel stained with Colloidal Blue Stain-
ing Kit (Thermo Fisher Scientific, cat. LC6025) and washed
thoroughly with ultrapure water prior to in-gel digestion.
In-gel digestion of purified glycoprotein
Excised bands corresponding to CEL were first destained in a
50% acetonitrile (MeCN) (v/v) solution in 50 mM ammonium
bicarbonate for 10 min, followed by incubation in 10 mM DTT
solution for 30 min at 56 °C. The gel pieces were desiccated,
followed by incubation with a 55 mM solution of iodoacetic acid
for 30 min in darkness at room temperature. The gel pieces
were desiccated again prior to incubation with 1 g of porcine
trypsin (Sigma-Aldrich, cat. S8045) in 50 mM ammonium bicar-
bonate, pH 8.5 (adjusted with ammonia), overnight at 37 °C.
Following extraction of the tryptic glycopeptides from the gel in
0.1% TFA/MeCN (1:2 v/v), the volume was reduced by a vac-
uum concentrator and the samples were freeze-dried by com-
plete lyophilizing before proceeding to reductive elimination.
All solvents used for glycan purification and analysis were
HPLC-grade or higher.
Release of O-glycans by reductive elimination
O-glycans were released from the mixture of peptides/glyco-
peptides by reductive elimination in 400 l of potassium boro-
hydride (55 mg/ml in 0.1 M potassium hydroxide) at 45 °C for
16 h. After the reaction had been terminated by dropwise addi-
tion of glacial acetic acid, the mixture was passed through a
Dowex beads 50W-X8 50 –100 mesh (Sigma-Aldrich, cat.
217492) chromatography column and the eluate was freeze-
dried. Excess borates were removed by co-evaporation with
repeated addition of 10% methanolic acetic acid under a stream
of nitrogen.
Permethylation of dried O-glycans
Two ml of a slurry composed of freshly crushed sodium
hydroxide pellets and DMSO was added to the sample, followed
by 600 l of methyl iodide. The mixture was vigorously mixed
on an automatic shaker for 45 min at room temperature. One
ml of water was added to terminate the reaction, followed by
another 1 ml of chloroform to recover the permethylated gly-
cans. The aqueous phase was washed three times to remove
impurities, and the chloroform layer was then dried under a
nitrogen stream. Permethylated O-glycans were purified using
a Sep-Pak Classic C18 cartridge (Waters). The cartridge was
conditioned successively with methanol, water, MeCN, and
water. The samples were dissolved in 1:1 (v/v) methanol-water,
loaded onto the cartridge, washed with water and 15% (v/v)
aqueous MeCN solution, and then eluted using a 35% (v/v)
aqueous MeCN solution. The organic solvent was removed on
a vacuum concentrator and samples were lyophilized overnight
prior to MS analyses.
MALDI-TOF MS
MALDI-TOF MS data on permethylated samples were
acquired in the reflectron positive-ion mode using a 4800
MALDI-TOF/TOF mass spectrometer (Applied Biosystems).
The instrument was calibrated externally using the Calmix
4700 calibration standard, samples were dissolved in 10 l of
methanol, and 1 l was mixed at a 1:1 ratio (v/v) with 20 mg/ml
3,4-diaminobenzophenone (DMBP) in 75% (v/v) MeCN in
water as matrix. The samples were then spotted onto a 384-
4 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party hosted site.
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well sample plate and dried at room temperature. Data were
acquired using 4000 Series Explorer instrument control soft-
ware and were processed using the software Data Explorer
(Version 4.9, Applied Biosystems). MS spectra were assigned
and annotated with the help of the GlycoWorkbench software
(65). Further MS/MS analyses of peaks observed in the MS
spectra were carried out using the same instrument. The poten-
tial difference between the source acceleration voltage and the
collision cell was set to 1 kV, and argon was used as collision gas.
Statistical analyses
Analyses were performed using GraphPad prism 5.03 for
Windows (GraphPad Software, San Diego CA).
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